TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01658553
Drug: GSK1120212
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1120212 - placebo match oral dose on day 1 with GSK1120212 3 mg oral dose on day 15. GSK1120212 2mg and 2 tablets of GSK1120212 -placebo matched 0.5 mg oral dose daily from day 2 to day 14. 24 hour holter monitoring will be performed on day 1 and day 15 to compare the subjects cardiac repolarization while on placebo and after having received GSK1120212 for 14 days
Study: NCT01864265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered according to the label of the biological
Study: NCT01244035
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8266 1.3 mg orally twice daily (BID, 1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
Study: NCT01244035
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8266 0.1 mg orally administered every 2 hours as frequent divided dosing (FDD, total dose of 0.9 mg) plus placebo to match Treatment A on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
Study: NCT02432937
Drug: Corever
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corever
Study: NCT00641108
Drug: ADAM SPECT plus Cognitive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00641108
Drug: ADAM SPECT plus No Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04527055
Drug: Tetracycline Pill
Normalized name: tetracycline Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
Study: NCT00886418
Drug: muscle relaxant
Normalized name: MUSCLE RELAXANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: muscle relaxant administration throughout anesthesia
Study: NCT00886418
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: no muscle relaxant throughout anesthesia (normal saline infused as a placebo)
Study: NCT03067792
Drug: 5-fluorouracil, irinotecan and leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5-fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle.
Study: NCT03899584
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo arm will include a placebo of microcrystalline cellulose.
Study: NCT04149483
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: One with the intervention (Placebo, 20mg OD), 30 patients for this arm.
Study: NCT01769833
Drug: Nucleosides
Normalized name: Nucleosides and nucleotides excl. reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01623505
Drug: Transdermal Nicoderm patch combined with gum or inhaler
Normalized name: Nicoderm C-Q Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receiving this treatment will set a quit date within 2 weeks after baseline assessment and apply the patch on that day. This group will follow the same regimen as the standard patch treatment, but is not limited to a fixed dosing strategy. Participants will be advised on the titration of patch (increase or decrease in dosage) to ensure elimination of withdrawal symptoms (maximum dosage of 35mg/day, maximum treatment of up to 22 weeks). Participants will be provided with either gum or inhaler to manage cravings.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.~\*Off-label dosage approved by Health Canada via No Objection letter.
Study: NCT01623505
Drug: Transdermal Nicoderm patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receiving this treatment group (standard treatment)will set a target quit date within the 2 weeks after baseline assessment and start to apply the patch on that day. This treatment will consist of a 10-week supply of nicotine patches. The initial dosage will be determined from the average number of cigarettes smoked each day as per the manufacturer's recommendation. Participants smoking ≥ 20 cigarettes per day will be prescribed 21 mg/24 hours for 6 weeks, 14 mg/24 hours for 2 weeks, and 7 mg/24 hours for 2 weeks. Participants smoking 11 - 20 cigarettes per day will be prescribed 14 mg/24 hours for 6 weeks, and 7 mg/24 hours for 4 weeks.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.
Study: NCT00507585
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m\^2 IV over 10 Minutes, then 600 mg/m\^2 IV over 22 Hours repeated every 3 weeks (1 Cycle).
Study: NCT00507585
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m\^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
Study: NCT01616277
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for PF-06252616, IV infusion, single dose
Study: NCT01616277
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for PF-06252616, Subcutaneous injection, single dose
Study: NCT01616277
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for PF-06252616, IV infusion, repeat dose
Study: NCT00373048
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, once weekly
Study: NCT04590599
Drug: IBI310
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI310 3 mg/kg,Q3W, for a total of 4 cycles
Study: NCT04590599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Q3W, for a total of 4 cycles
Study: NCT01354522
Drug: Docetaxel, Doxorubicin, Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
Study: NCT01354522
Drug: Docetaxel, Cyclophosphamide, Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles
Study: NCT00003262
Drug: Stanford V regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003262
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02651116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL Placebo
Study: NCT01355614
Drug: QAX576
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00421148
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT03491033
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: All of the patients in this study underwent NAC regimens consisting of taxane and platinum combination chemotherapy. After NAC, all of the patients underwent interval debulking surgery. Subsequently, additional cycles of chemotherapy were administered after IDS to complete a total of 6 cycles at the discretion of the treating physician.
Study: NCT01284959
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactose PO, 3times
Study: NCT03924544
Drug: Decorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifibrotic agent
Study: NCT02393339
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-operative administration of placebo syrup
Study: NCT02546583
Drug: IV Chlorothiazide
Normalized name: Chlorothiazide
DrugBank: Chlorothiazide (DB00880)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00401843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as intravenous infusion once every 2 weeks during 42-day treatment phase and 35-day maintenance phase in Part 2.
Study: NCT02272946
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg Placebo received subcutaneously
Study: NCT00178971
Drug: adjunctive treatment with buspirone
Approvals — FDA: no, EMA: no, PMDA: no
Description: buspirone 15-30 mg qd
Study: NCT00178971
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00002548
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.5 g/m2 in 100 ml of D5W, IV intravenously over 1 hour every 3 hour x 3 (total dose 4.5 g/m2)
Study: NCT00002548
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m2/day continuous 1 - 4 q 5 weeks
Study: NCT02030821
Drug: TXA
Normalized name: TXA>2<
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to receive TXA will receive this during surgical intervention
Study: NCT02153489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02405988
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administer remifentanil intravenously by way of Target Control Infusion, Minto's model at a target of 1,3 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone.
Study: NCT04067492
Drug: Voltaren®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated tablets, 25 mg and 50 mg
Study: NCT02102243
Drug: DEFINITY® infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: The DEFINITY® vial contains components that upon activation yield perflutren lipid microspheres, a diagnostic drug that is intended to be used for contrast enhancement during echocardiographic procedures. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic liquid, which upon activation with agitation, provides a homogeneous, opaque, milky white injectable suspension of perflutren lipid microspheres. The suspension of activated DEFINITY® will be infused intravenously at a rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit.
Study: NCT02102243
Drug: Human Recombinant Regular Insulin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: The plasma insulin concentration will be acutely raised and maintained at at a steady state by a prime-continuous insulin infusion.
Study: NCT02746328
Drug: GTx-024 9 or 18 mg
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients enrolled in G200802 receiving GTx-024 9 or 18 mg
Study: NCT03837990
Drug: Helicobacter Pylori eradication therapy
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy includes the administration of a proton pump inhibitor (PPI) and antibiotics. Triple therapy with a PPI (lansoprazole or esomeprazole), clarithromycin, and amoxicillin is the first-line regimen. Quadruple therapy with a PPI, bismuth, metronidazole, and tetracyclin is the second-line therapy.
Study: NCT02947633
Drug: Continuous sciatic PNB
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous sciatic PNB entails placing a continuous perineural infusion (CPI) catheter so that local anesthetic may be released slowly but continuously adjacent to the sciatic nerve (perineural) for several days postoperatively. The continuous PNB has the ability to reliably provide analgesia on subsequent postoperative days.~Participants my be randomized to receive an additional experimental continuous pain ball during surgery which can provide up to 48 hours of pain relief.
Study: NCT00444925
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily (OD)for 12 weeks
Study: NCT01406132
Drug: ASP015K
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00572598
Drug: 4- [F-18] fluoropaclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4- \[F-18\] fluoropaclitaxel, \<84 micrograms, \<10 mCi, IV followed by PET/CT imaging
Study: NCT02911142
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During cycle 1, Doxorubicin 10 mg /m2/day continuous intravenous infusion days 6 to 9. During cycles 2-6, Doxorubicin continuous intravenous infusion days 1 to 4.
Study: NCT02911142
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During cycle 1, Cyclophosphamide 750 mg/m2 day 10. During cycles 2-6, Cyclophosphamide 750 mg/m2 day 5.
Study: NCT02131662
Drug: BAY1002670
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received 4 milligram (mg) Vilaprisan (VPR) tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Study: NCT02131662
Drug: BAY1002670
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received 2 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Study: NCT02131662
Drug: BAY1002670
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received 1 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Study: NCT02131662
Drug: BAY1002670
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received 0.5 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Study: NCT02131662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received matching placebo tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Study: NCT01402869
Drug: 2% Lidocaine with 1:100,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mg/kg via infiltration into multiple sites of buccal mucosa of mouth 1 time prior to restorative dental treatment
Study: NCT00038844
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 gm/m2 by vein daily, 3 days in a row.
Study: NCT01052883
Drug: DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment C\], then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment D\]
Study: NCT01052883
Drug: DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 \[Treatment B\], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment A\]
Study: NCT01052883
Drug: DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment D\], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment C\]
Study: NCT01052883
Drug: DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment A\], then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment B\]
Study: NCT02619747
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00295607
Drug: steroids, monoclonal anti-IL2R antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: immunosuppression
Study: NCT01521598
Drug: SKL11197
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKL11197 drug product contains 150 mg of active ingredient. Dosing will be three times per day.
Study: NCT01521598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is the placebo. Patients will be randomized the placebo.
Study: NCT01451749
Drug: Shenwu Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 shenwu capsule contains 451 mg extract from herbs.5 capsules/time, 3 times/day for 6 months.~Placebo identified to donepezil: 1 tablet per time, 1 time per day for 6 months.
Study: NCT01771874
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: per os
Study: NCT02264613
Drug: ALRN-6924
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALRN-6924 will be administered as an IV infusion
Study: NCT02524249
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02524249
Drug: Placebo (dextrose)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03159975
Drug: GX-70 by electroporation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gx-70 0.26mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
Study: NCT03159975
Drug: GX-70 by electroporation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gx-70 1mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
Study: NCT03159975
Drug: GX-70 by electroporation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gx-70 4mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
Study: NCT00315510
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00921050
Drug: levothyroxine sodium
Normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily intake (fasting) levothyroxine bimonthly adjusted; to keep TSH between 0.5 to 2.5 mUI/L range. Start with 12.5mcg an investigator other than the caregiver will review the TSH measurements to adjust levothyroxine dose that will contain the coded bottle with the pils given to patient.
Study: NCT00921050
Drug: excipient without levothyroxine (placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake (fasting) a pill. bimonthly adjusted; an investigator other than the caregiver will review the TSH measurements and pretend to adjust dose contained in the coded bottle with the pills given to patient.
Study: NCT04396821
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 is a combination chemotherapy regimen including the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
Study: NCT01023100
Drug: CP 690,550 oral solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: flavored and unflavored prototype CP-690,550 formulations
Study: NCT02664155
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Of Care
Study: NCT03160560
Drug: ClōSYS® Unflavored Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in Test group will receive ClōSYS® Unflavored Rinse.
Study: NCT03941483
Drug: ASP1128
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Infusion
Study: NCT03941483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Infusion
Study: NCT03160560
Drug: ClōSYS® Flavored Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in Test group will receive ClōSYS® Flavored Rinse.
Study: NCT03440866
Drug: Administration of drugs concomitantly.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of oral Mifepristone 600 mg and oral Misoprostol 400 mcg concomitantly.
Study: NCT01085526
Drug: Alutard phl prat
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00928343
Drug: GLPG0187
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending subcutaneous doses (subcutaneous solution), and single oral dose (oral solution)
Study: NCT00928343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching subcutaneous or oral placebo
Study: NCT03154476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matching study drug
Study: NCT03938831
Drug: Fentanyl-based PCA infusion
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl-based PCA infusion
Study: NCT03549338
Drug: Sym004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
Study: NCT00005903
Drug: GDNF & Synchro Med Infusion System
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00755807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo oral (po), once daily (QD) for 6 weeks (acute phase). If the participant completes the 6-week double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 milligrams \[mg\] QD for 12 weeks).
Study: NCT00157963
Drug: MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00626535
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Once Daily
Study: NCT00003873
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or orally
Study: NCT00507442
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide 500 mg/m\^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop
Study: NCT03076281
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT03076281
Drug: Metformin +Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT03549741
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets
Study: NCT00174850
Drug: Gaitril
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01761513
Drug: YH4808
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group1~1. adminitration of YH4808 dose1, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, qd for 2weeks